The investigational immuno-oncology combination of efti and KEYTRUDA achieved an objective response rate (ORR) of 35.5% (11 of 31 evaluable patients) and a disease control rate (DCR) of 58.1%, according to RECIST 1.1, in 1L HNSCC patients whose tumors do not express PD-L1 (Combined Positive Score [CPS] 20 PD-L1 expression levels are approximately 20%, 30%, and 50% of the HNSCC patient population, respectively
Lyophilized peptides are stable at room temperature for weeks, but for longer-term storage, it is safer to store them at -20 C or colder
This report will break down your insurance coverage for each GLP-1 medication and whether your policy requires prior authorization
A lack of significant weight loss during the first month does not necessarily mean the treatment will be ineffective
Ozempic is one of the most effective medicines to manage Type 2 Diabetes
No questions about medication potency